Telomir Pharmaceuticals (NASDAQ: TELO) announced an approximately $5.6 million private investment in public equity (PIPE) financing through the issuance of 4,843,300 common shares at $1.16 per share, representing a 5% discount to the applicable 10-day volume-weighted average price. The financing includes an additional $1 million investment from existing significant shareholder John Paul DeJoria and does not include investor warrants, convertible securities or variable-price or reset features. The company intends to use the net proceeds primarily to support clinical development of Telomir-Zn, including its Phase 1/2 clinical program in advanced or metastatic triple-negative breast cancer (TNBC), as well as for working capital and general corporate purposes.
The FDA has cleared the company's Investigational New Drug application for Telomir-Zn, enabling it to proceed with its first-in-human Phase 1/2 trial in patients with advanced or metastatic TNBC. This clearance marks a critical step for Telomir as it transitions into clinical-stage testing of its lead candidate. The financing structure, devoid of warrants and reset provisions, may be viewed favorably by investors as it minimizes potential dilution and complexity. The participation of DeJoria, a prominent entrepreneur and existing shareholder, signals continued confidence in the company's direction.
Triple-negative breast cancer is an aggressive subtype with limited treatment options, and new therapies are urgently needed. Telomir-Zn is designed to modulate intracellular metal homeostasis and epigenetic regulation, representing a novel approach that could potentially address unmet medical needs. If successful, the Phase 1/2 trial could pave the way for further development and eventual commercialization, offering hope to patients and a potential new revenue stream for Telomir.
For more details, the full press release is available at https://ibn.fm/0KMpl. The latest news and updates relating to TELO are available in the company's newsroom at https://ibn.fm/TELO. Telomir Pharmaceuticals is a clinical-stage biotechnology company developing small-molecule therapeutics targeting epigenetic and metabolic pathways implicated in cancer.
The announcement was distributed by InvestorWire, a specialized communications platform with a focus on advanced wire-grade press release syndication. InvestorWire is one of 75+ brands within the Dynamic Brand Portfolio at IBN, which delivers access to a vast network of wire solutions, article and editorial syndication to 5,000+ outlets, enhanced press release enhancement, social media distribution to millions of followers, and a full array of tailored corporate communications solutions. This infrastructure ensures that news like Telomir's financing reaches a wide audience of investors, influencers, consumers, journalists, and the general public. For full terms of use and disclaimers applicable to all content provided by InvestorWire, visit https://www.InvestorWire.com/Disclaimer.
The successful PIPE financing provides Telomir with the necessary capital to advance its clinical program without the overhang of warrants, potentially attracting long-term investors. It also underscores the growing interest in novel cancer therapies, particularly for hard-to-treat subtypes like TNBC. As the company moves forward with its first-in-human trial, the results will be closely watched by the biotech industry and could influence future investment in epigenetic and metabolic cancer therapeutics.
